Gilead Sciences Inc (GILD)

$143.28 +0.39 (0.27%)
Market Cap 176.11B
Revenue (ttm) 28.75B
Net Income (ttm) 480.00M
EPS (ttm) N/A
PE Ratio 17.04
Forward PE 16.23
Profit Margin 1.67%
Debt to Equity Ratio 1.16
Volume 6,840,100
Avg Vol 7,209,636
Day's Range N/A - N/A
Shares Out 1.24B
Stochastic %K 96%
Beta 0.33
Analysts Strong Sell
Price Target $138.44

Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis....

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 650 574 3000
Fax: 650 578 9264
Address:
333 Lakeside Drive, Foster City, United States
Ro_Patel
Ro_Patel Feb. 3 at 10:44 PM
Medicare drug price negotiations to include treatments administered in doctors’ offices, including some for Type 2 diabetes, HIV, cancer & arthritis. These are drugs covered in Medicare Part B. Only retail medications covered by Part D were eligible for the talks during the previous two rounds of discussions. The negotiated prices for the 15 drugs chosen this year will take effect in 2028. About 1.8M beneficiaries used these medications b/n Nov 2024 & Oct 2025, and they accted for about $27B in Medicare Part B & D spending Note: 14 of the drugs, Medicare revs exposed to the negotiations represents only 0% to 3% of the companies’ worldwide 2027 sales. $GILD Biktarvy, a once-daily pill that treats HIV, draws significant sales from Medicare, representing around 8% of Gilead’s est'd global FY27 revs $LLY $ABBV $GSK $PFE
0 · Reply
ZacksResearch
ZacksResearch Feb. 3 at 6:31 PM
$GILD surges 20.8% in a month — what’s driving the rally? 🚀 Much of the rally followed the Jan. 21 announcement that full results from the ASCENT-04 study were published in NEJM, showing a 35% reduced risk of disease progression or death with Trodelvy + Keytruda in metastatic TNBC, suggesting a potential new standard of care. 📈 Discover the full impact on Gilead's outlook here 👉 https://www.zacks.com/stock/news/2827790/heres-why-gilead-sciences-stock-surged-21-in-a-month?cid=sm-stocktwits-2-2827790-body-31804&ADID=SYND_STOCKTWITS_TWEET_2_2827790_BODY_31804
0 · Reply
WAJeff
WAJeff Feb. 3 at 3:24 PM
$GILD $145.94 ath
0 · Reply
DefenseMania
DefenseMania Feb. 3 at 2:45 PM
$GILD $175 inbound 💰💰💰💰
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Feb. 3 at 2:44 PM
$INBS : Redefining the Future of Drug Screening Intelligent Bio Solutions is a diagnostics technology company advancing drug testing with a proprietary, non-invasive fingerprint sweat analysis platform, delivering fast, hygienic results as an alternative to traditional urine and saliva testing. 📈 Recent Milestones & Key Catalysts: INBS continues to execute on its growth strategy with several notable developments: 🥇FDA 510(k) submission, positioning the company for entry into the U.S. market 🥈Expansion of manufacturing capacity through a strategic global partner, improving scalability and margins 🥉Latest company update reporting approximately $13.78M in total assets versus $5.45M in total liabilities ➡️A growing commercial footprint with over 450 customers across 24 countries ➡️Ongoing innovation initiatives aimed at expanding non-invasive biosensing applications Communicated Disclaimer: http://stockresearchtoday.com/transforming-d… Sector Peers: $MRNA $CRSP $GILD $CDMO
0 · Reply
WAJeff
WAJeff Feb. 2 at 8:12 PM
$GILD $143.79 ath
0 · Reply
BTECHINV
BTECHINV Feb. 1 at 10:15 PM
$ALT Jeffries reiterated $ 28 PT is a conservative, risk-adjusted figure imo (i.e. recognition that drug candidate is still in clinical trial development). Assuming a successful P3 & NDA, the re-rate would be much closer to MDGL territory imo. BP's who could benefit in my view: $SNY - instantly establishes one of the top global GCGR (and GLP-1) drug pipelines in Pharma with Pemvi $GILD - establishes dominance across the Liver steatosis spectrum (i.e. complements world-class PBC and Hepatitis franchises) $MDGL - establishes a world-class next-gen MOA Liver drug portfolio (THR-B, GCGR) $PFE - potential to transform Pemvi into the equivalent of the cardiometabolic disease age Lipitor 2.0 Disclosure: Long Altimmune (Pemvi GCGR) and Sanofi, not medical / investment advice.
2 · Reply
harmongreg
harmongreg Feb. 1 at 6:42 PM
5 Trade Ideas for Monday: Apple, Bank of America, Gilead, Hartford Insurance and Walmart $AAPL $BAC $GILD $HIG $WMT https://dragonflycap.com/5-trade-ideas-for-monday-apple-bank-of-america-gilead-hartford-insurance-and-walmart/
0 · Reply
WAJeff
WAJeff Jan. 31 at 6:47 AM
$GILD $142.20 ath today, I’ll be damned. That’s some serious strength
1 · Reply
Reanimated666
Reanimated666 Jan. 30 at 3:01 PM
$GILD oasis
0 · Reply
Latest News on GILD
Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026

Jan 27, 2026, 4:05 PM EST - 7 days ago

Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026

New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer

Jan 21, 2026, 5:00 PM EST - 13 days ago

New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer

Gilead Sciences: Margin Expansion And Cash Flow Strength Underpriced

Jan 20, 2026, 1:03 PM EST - 14 days ago

Gilead Sciences: Margin Expansion And Cash Flow Strength Underpriced

Gilead: A Top GARP Biotech Play, But Momentum Weakens (Downgrade)

Jan 16, 2026, 1:41 PM EST - 18 days ago

Gilead: A Top GARP Biotech Play, But Momentum Weakens (Downgrade)

Gilead Sciences: From All-Time Highs To Higher Highs

Jan 12, 2026, 5:40 PM EST - 22 days ago

Gilead Sciences: From All-Time Highs To Higher Highs

Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says

Jan 12, 2026, 3:58 PM EST - 22 days ago

Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says

CVS

Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 3:46 PM EST - 22 days ago

Gilead Sciences, Inc. (GILD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history

Jan 12, 2026, 9:21 AM EST - 22 days ago

Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history

OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead's Drug Candidate

Jan 6, 2026, 7:00 AM EST - 4 weeks ago

OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead's Drug Candidate

Gilead Sciences to Present at Upcoming Investor Conference

Dec 22, 2025, 4:05 PM EST - 6 weeks ago

Gilead Sciences to Present at Upcoming Investor Conference

Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

Dec 22, 2025, 8:00 AM EST - 6 weeks ago

Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

ASMB

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

Dec 19, 2025, 4:09 PM EST - 6 weeks ago

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

BMY GSK MRK AMGN NVS SNY

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

Dec 19, 2025, 3:14 PM EST - 6 weeks ago

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

AMGN BMY GSK MRK NVS SNY

Nine of the largest pharma companies ink deals with Trump to lower drug prices

Dec 19, 2025, 2:34 PM EST - 6 weeks ago

Nine of the largest pharma companies ink deals with Trump to lower drug prices

AMGN BMY GSK MRK NVS SNY

Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans

Dec 19, 2025, 2:21 PM EST - 6 weeks ago

Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans

Trump to announce new drug-pricing deals later today

Dec 19, 2025, 10:45 AM EST - 6 weeks ago

Trump to announce new drug-pricing deals later today

ABBV AMGN AZN BMY LLY MRK NVO

Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance

Dec 18, 2025, 8:30 AM EST - 6 weeks ago

Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance

Gilead's experimental HIV treatment meets main goal in late-stage trial

Dec 15, 2025, 8:43 AM EST - 7 weeks ago

Gilead's experimental HIV treatment meets main goal in late-stage trial

Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial

Dec 15, 2025, 8:30 AM EST - 7 weeks ago

Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial

Gilead, Arcus scrap late-stage trial of cancer drug combo

Dec 12, 2025, 8:36 AM EST - 7 weeks ago

Gilead, Arcus scrap late-stage trial of cancer drug combo

Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer

Dec 9, 2025, 8:30 AM EST - 2 months ago

Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer

Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025

Dec 7, 2025, 8:00 AM EST - 2 months ago

Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025

Kite's Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025

Dec 6, 2025, 2:00 PM EST - 2 months ago

Kite's Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025

Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma

Dec 6, 2025, 2:00 PM EST - 2 months ago

Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma

Gilead Sciences, Inc. (GILD) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 3, 2025, 3:13 PM EST - 2 months ago

Gilead Sciences, Inc. (GILD) Presents at Evercore 8th Annual Healthcare Conference Transcript

Gilead Sciences, Inc. (GILD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 1:23 AM EST - 2 months ago

Gilead Sciences, Inc. (GILD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Gilead Sciences: About To Break Out

Nov 25, 2025, 6:17 AM EST - 2 months ago

Gilead Sciences: About To Break Out

Gilead Foundation Commits Over $3 Million to Address Food Insecurity

Nov 24, 2025, 8:30 AM EST - 2 months ago

Gilead Foundation Commits Over $3 Million to Address Food Insecurity

Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength

Nov 20, 2025, 4:46 PM EST - 2 months ago

Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength

$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield

Nov 20, 2025, 11:17 AM EST - 2 months ago

$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield

AMGN BMY IVV MRK PFE SPY VOO

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs

Nov 20, 2025, 7:02 AM EST - 2 months ago

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs

Gilead Sciences, Inc. (GILD) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 19, 2025, 11:23 AM EST - 2 months ago

Gilead Sciences, Inc. (GILD) Presents at Jefferies London Healthcare Conference 2025 Transcript

Global drugmakers rush to boost US presence as tariff threat looms

Nov 18, 2025, 8:25 AM EST - 2 months ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN BIIB GSK JNJ LLY

Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

Nov 18, 2025, 5:00 AM EST - 2 months ago

Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial

Nov 13, 2025, 1:55 PM EST - 2 months ago

Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial

Can Gilead Stock Outrun Regeneron In The Next Rally?

Nov 13, 2025, 9:00 AM EST - 2 months ago

Can Gilead Stock Outrun Regeneron In The Next Rally?

Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial

Nov 13, 2025, 8:30 AM EST - 2 months ago

Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial

Gilead Sciences, Inc. (GILD) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 2:41 PM EST - 3 months ago

Gilead Sciences, Inc. (GILD) Presents at UBS Global Healthcare Conference 2025 Transcript

AHF's Mobile Billboard Calls Out Gilead's Greed at Pharma Summit

Nov 10, 2025, 4:00 AM EST - 3 months ago

AHF's Mobile Billboard Calls Out Gilead's Greed at Pharma Summit

Gilead's breast cancer drug fails to meet main goal of late-stage study

Nov 7, 2025, 8:41 AM EST - 3 months ago

Gilead's breast cancer drug fails to meet main goal of late-stage study

Gilead Provides Update on Phase 3 ASCENT-07 Study

Nov 7, 2025, 8:30 AM EST - 3 months ago

Gilead Provides Update on Phase 3 ASCENT-07 Study

Gilead's Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression

Nov 7, 2025, 8:00 AM EST - 3 months ago

Gilead's Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression

Gilead Sciences to Present at Upcoming Investor Conferences

Nov 4, 2025, 4:05 PM EST - 3 months ago

Gilead Sciences to Present at Upcoming Investor Conferences

Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025

Nov 3, 2025, 9:10 AM EST - 3 months ago

Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025

Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026

Oct 31, 2025, 1:41 PM EDT - 3 months ago

Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026

Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)

Oct 31, 2025, 8:00 AM EDT - 3 months ago

Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)

Gilead Sciences, Inc. (GILD) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 8:56 PM EDT - 3 months ago

Gilead Sciences, Inc. (GILD) Q3 2025 Earnings Call Transcript

Gilead posts higher profit as HIV sales rise, helped by prevention drugs

Oct 30, 2025, 4:05 PM EDT - 3 months ago

Gilead posts higher profit as HIV sales rise, helped by prevention drugs

Gilead Sciences Announces Third Quarter 2025 Financial Results

Oct 30, 2025, 4:02 PM EDT - 3 months ago

Gilead Sciences Announces Third Quarter 2025 Financial Results

Victory! AHF, 100 Organizations Kill Gilead's Greedy Drug Price Hikes

Oct 29, 2025, 4:11 PM EDT - 3 months ago

Victory! AHF, 100 Organizations Kill Gilead's Greedy Drug Price Hikes

Ro_Patel
Ro_Patel Feb. 3 at 10:44 PM
Medicare drug price negotiations to include treatments administered in doctors’ offices, including some for Type 2 diabetes, HIV, cancer & arthritis. These are drugs covered in Medicare Part B. Only retail medications covered by Part D were eligible for the talks during the previous two rounds of discussions. The negotiated prices for the 15 drugs chosen this year will take effect in 2028. About 1.8M beneficiaries used these medications b/n Nov 2024 & Oct 2025, and they accted for about $27B in Medicare Part B & D spending Note: 14 of the drugs, Medicare revs exposed to the negotiations represents only 0% to 3% of the companies’ worldwide 2027 sales. $GILD Biktarvy, a once-daily pill that treats HIV, draws significant sales from Medicare, representing around 8% of Gilead’s est'd global FY27 revs $LLY $ABBV $GSK $PFE
0 · Reply
ZacksResearch
ZacksResearch Feb. 3 at 6:31 PM
$GILD surges 20.8% in a month — what’s driving the rally? 🚀 Much of the rally followed the Jan. 21 announcement that full results from the ASCENT-04 study were published in NEJM, showing a 35% reduced risk of disease progression or death with Trodelvy + Keytruda in metastatic TNBC, suggesting a potential new standard of care. 📈 Discover the full impact on Gilead's outlook here 👉 https://www.zacks.com/stock/news/2827790/heres-why-gilead-sciences-stock-surged-21-in-a-month?cid=sm-stocktwits-2-2827790-body-31804&ADID=SYND_STOCKTWITS_TWEET_2_2827790_BODY_31804
0 · Reply
WAJeff
WAJeff Feb. 3 at 3:24 PM
$GILD $145.94 ath
0 · Reply
DefenseMania
DefenseMania Feb. 3 at 2:45 PM
$GILD $175 inbound 💰💰💰💰
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Feb. 3 at 2:44 PM
$INBS : Redefining the Future of Drug Screening Intelligent Bio Solutions is a diagnostics technology company advancing drug testing with a proprietary, non-invasive fingerprint sweat analysis platform, delivering fast, hygienic results as an alternative to traditional urine and saliva testing. 📈 Recent Milestones & Key Catalysts: INBS continues to execute on its growth strategy with several notable developments: 🥇FDA 510(k) submission, positioning the company for entry into the U.S. market 🥈Expansion of manufacturing capacity through a strategic global partner, improving scalability and margins 🥉Latest company update reporting approximately $13.78M in total assets versus $5.45M in total liabilities ➡️A growing commercial footprint with over 450 customers across 24 countries ➡️Ongoing innovation initiatives aimed at expanding non-invasive biosensing applications Communicated Disclaimer: http://stockresearchtoday.com/transforming-d… Sector Peers: $MRNA $CRSP $GILD $CDMO
0 · Reply
WAJeff
WAJeff Feb. 2 at 8:12 PM
$GILD $143.79 ath
0 · Reply
BTECHINV
BTECHINV Feb. 1 at 10:15 PM
$ALT Jeffries reiterated $ 28 PT is a conservative, risk-adjusted figure imo (i.e. recognition that drug candidate is still in clinical trial development). Assuming a successful P3 & NDA, the re-rate would be much closer to MDGL territory imo. BP's who could benefit in my view: $SNY - instantly establishes one of the top global GCGR (and GLP-1) drug pipelines in Pharma with Pemvi $GILD - establishes dominance across the Liver steatosis spectrum (i.e. complements world-class PBC and Hepatitis franchises) $MDGL - establishes a world-class next-gen MOA Liver drug portfolio (THR-B, GCGR) $PFE - potential to transform Pemvi into the equivalent of the cardiometabolic disease age Lipitor 2.0 Disclosure: Long Altimmune (Pemvi GCGR) and Sanofi, not medical / investment advice.
2 · Reply
harmongreg
harmongreg Feb. 1 at 6:42 PM
5 Trade Ideas for Monday: Apple, Bank of America, Gilead, Hartford Insurance and Walmart $AAPL $BAC $GILD $HIG $WMT https://dragonflycap.com/5-trade-ideas-for-monday-apple-bank-of-america-gilead-hartford-insurance-and-walmart/
0 · Reply
WAJeff
WAJeff Jan. 31 at 6:47 AM
$GILD $142.20 ath today, I’ll be damned. That’s some serious strength
1 · Reply
Reanimated666
Reanimated666 Jan. 30 at 3:01 PM
$GILD oasis
0 · Reply
Sunny3999
Sunny3999 Jan. 30 at 1:55 PM
$PMN before news of $175 million I wrote this will be a 10bagger $AMGN $GILD $LLY $REGN
0 · Reply
Sunny3999
Sunny3999 Jan. 30 at 1:19 PM
$PMN Wow news $175 million private placement https://www.promisneurosciences.com/news-media/press-releases/detail/261/promis-neurosciences-announces-up-to-175-million-private $AMGN $GILD $LLY $REGN
0 · Reply
Sunny3999
Sunny3999 Jan. 30 at 1:12 PM
$PMN News with news $175 million private placement https://www.promisneurosciences.com/news-media/press-releases/detail/261/promis-neurosciences-announces-up-to-175-million-private $AMGN $GILD $LLY $REGN
0 · Reply
IN0V8
IN0V8 Jan. 29 at 7:39 PM
$GILD TD Cowen raises target price to $145 from $125
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Jan. 28 at 10:48 PM
$GILD Trading around $140, bouncing off the recent high of $140.97. Support seen near $135 with average volume around 7.9 million. Volatility looks pretty high with recent price swings.
0 · Reply
Sunny3999
Sunny3999 Jan. 28 at 7:32 PM
$PMN hidden gem 💎 ready to rip! https://www.promisneurosciences.com/investors/news-events/press-releases/detail/246/promis-neurosciences-granted-fast-track-designation-by-u-s $AMGN $GILD $LLY $PMN $REGN
0 · Reply
clan
clan Jan. 28 at 6:53 PM
$JNJ $GILD $CIPLA.NSE Who here knew there is an INHALABLE mealtime insulin?!? Holy smokes! 😲 No more shooting up at meals for diabetics!❤️
0 · Reply
Sunny3999
Sunny3999 Jan. 28 at 6:31 PM
$PMN Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk https://www.promisneurosciences.com/investors/news-events/press-releases/detail/259/promis-neurosciences-announces-new-peer-reviewed $AMGN $GILD $LLY $REGN
0 · Reply
Sunny3999
Sunny3999 Jan. 28 at 5:46 PM
$PMN It’s ripe to rip! From last PR: “This is a major execution milestone for ProMIS and a potentially pivotal moment for the Alzheimer’s field” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences. “Completing enrollment and above our target in a rigorously designed, biomarker-rich study of this scale positions us to potentially confirm, clinically and biologically, for the first time the central role of toxic amyloid-beta oligomers in Alzheimer’s disease. The safety profile we have observed thus far, with no treatment-related SAEs and minimal dropouts, reinforces our belief that PMN310 may offer a fundamentally differentiated approach that has the potential to significantly reduce the ARIA liability that has limited broader use of current therapies. We believe the over-enrollment of PRECISE-AD may reflect strong enthusiasm among both patients and trial physicians for PMN310’s differentiated mechanism and its potential for improved safety $AMGN $GILD $LLY $REGN
0 · Reply
THE_Monkey_Banana_Genius
THE_Monkey_Banana_Genius Jan. 27 at 7:57 PM
$GILD WOW
1 · Reply
THE_Monkey_Banana_Genius
THE_Monkey_Banana_Genius Jan. 27 at 7:56 PM
$GILD did I get any? NO. Am I dumb? YES
1 · Reply
Reanimated666
Reanimated666 Jan. 27 at 6:32 PM
$GILD Took a little off a very overweighted position Still extremely bullish
0 · Reply